Claims
- 1. A composition comprising a stresscopin peptide, wherein said stresscopin peptide comprises at least 18 contiguous amino acids of the sequence set forth in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:6.
- 2. A composition according to claim 1, wherein said peptide comprises at least 30 contiguous amino acids of the sequence set forth in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:6.
- 3. The composition according to claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier.
- 4. A method of appetite suppression, the method comprising administering to an individual the composition of claim 3.
- 5. A method for cardioprotection, the method comprising administering to an individual the composition of claim 3.
- 6. A method for reduction of edema, the method comprising comprising administering to an individual the composition of claim 3.
- 7. A method for reduction of inflammation, and organ graft rejection the method comprising administering to an individual the composition of claim 3.
- 8. A method for the reduction of hypertension, the method comprising administering to an individual the composition of claim 3.
- 9. A method for the treatment of stress related to trauma, the method comprising administering to an individual the composition of claim 3.
- 10. A method of treatment for affective disorders, the method comprising comprising administering to an individual the composition of claim 3.
- 11. An isolated nucleic acid molecule comprising a cDNA sequence encoding a mammalian stresscopin protein that will hybridize under stringent conditions of 50° C. or higher in the presence of 0.1×SSC to the sequence set forth in any one of SEQ ID NO:1 or SEQ ID NO:4, or encodes the peptide in any one of SEQ ID NO:3 or SEQ ID NO:6.
- 12. An isolated nucleic acid according to claim 11, wherein said cDNA sequence is of human origin.
- 13. An isolated nucleic acid molecule according to claim 12, wherein said human stresscopin protein comprises the sequence set forth in any one of SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:5 or SEQ ID NO:6.
- 14. An isolated nucleic acid molecule according to claim 13, wherein said nucleic acid comprises the nucleotide sequence of SEQ ID NO:1 or SEQ ID NO:4.
- 15. The nucleic acid of claim 11, further comprising a vector sequence.
- 16. The nucleic acid of claim 15, wherein said vector comprises a transcription cassette operably linked to said stresscopin cDNA sequence.
- 17. The nucleic acid of claim 15, wherein said vector is a plasmid.
- 18. The nucleic acid of claim 15, wherein said vector is a retrovirus.
- 19. The nucleic acid of claim 15, wherein said vector is an adenovirus.
- 20. An antibody that specifically recognizes a stresscopin peptide.
- 21. A non-human transgenic animal model for stresscopin gene function wherein said transgenic animal comprises an introduced alteration in a stresscopin gene.
- 22. A method of screening for biologically active agents that modulate stresscopin function, the method comprising: combining a candidate biologically active agent with any one of:(a) a mammalian stresscopin peptide;(b) a cell comprising a nucleic acid encoding a mammalian stresscopin peptide; or(c) a non-human transgenic animal model for stresscopin gene function comprising one of:(i) a knockout of an stresscopin gene; (ii) an exogenous and stably transmitted mammalian stresscopin gene sequence; and determining the effect of said agent on stresscopin function.
CROSS REFERENCE OF RELATED APPLICATIONS
[0001] This application claims benefit of prior U.S. provisional application serial Nos. 60/244,1 28 filed Oct. 26, 2000 and 60/276,615 filed Mar. 15, 2001, both of which are incorporated herein in their entirety by reference.
Provisional Applications (2)
|
Number |
Date |
Country |
|
60244128 |
Oct 2000 |
US |
|
60276615 |
Mar 2001 |
US |